Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global AI in genomics market was valued at USD 879.29 Million in 2025. It is poised to grow at a CAGR of 32.40% during the forecast period of 2026-2035, and reach USD 14554.99 Million by 2035. The market growth is driven by the rising demand for precision medicine, increasing genomic data generation, and advancements in AI-driven analytics, which enable faster disease identification, improved diagnostics, and enhanced drug discovery efficiency globally.
Geopolitical Impact of Iran, US, and Israel War on the AI in Genomics Market
United States: The AI in Genomics Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, with similar revisions across other markets as corporate CFOs apply caution in an inflationary, uncertain macroeconomic environment. Microsoft Azure and AWS reported investigating latency spikes at Middle Eastern data center nodes following missile strikes on Dubai and Doha infrastructure. Semiconductor and electronics supply chains routed through the Gulf region are experiencing disruption, with some production inputs stranded aboard ships unable to transit the Strait of Hormuz. IDC revised U.S. IT spending growth from 12.4% to 11.4% for 2026, reflecting corporate caution in an inflationary environment. Despite overall caution, AI-driven infrastructure investment continues to provide structural demand support. Despite spending caution, AI infrastructure investment continues to grow, with the current crisis reinforcing the case for advanced technology adoption to offset rising labor and materials costs.
Iran: Iran's domestic AI in Genomics sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.
Israel: Israel's technology sector, a globally significant innovation hub for cybersecurity, semiconductors, AI, and various specialized verticals, is experiencing operational disruption as engineering teams are reduced by military reservist call-ups. Several Israeli companies supply components, software, and services to global AI in Genomics market participants. Business development activities have been suspended, and some operational timelines extended. However, Israel's proven resilience through previous conflict periods, and the continued operation of critical R&D programmes, suggests the disruption will be temporary rather than structural.
Government
Market
Procurement
Base Year
Historical Period
Forecast Period
In October 2025, AstraZeneca entered a USD 555 million partnership integrating AI with CRISPR-based genomics to identify immunology drug targets. This highlights growing industry reliance on AI-genomics convergence to accelerate early-stage discovery and therapeutic innovation.
In May 2025, BioNTech announced a 1 billion Pounds investment in the UK to establish AI and genomics research centers focused on personalized cancer therapies. The initiative strengthens AI integration in genomic-based vaccine and oncology research.
In May 2025, Mapmygenome acquired Microbiome Insights to enhance its AI-driven genomics and microbiome analysis capabilities, strengthening its position in precision health and expanding its global genomics portfolio.
Integrating AI in genomics significantly enhances data interpretation, enabling faster identification of genetic variations and improving diagnostic accuracy. It accelerates drug discovery, supports precision medicine, and streamlines large-scale genomic analysis. AI-driven tools also reduce costs and improve scalability, allowing researchers to process complex datasets efficiently. Additionally, predictive analytics aids in early disease detection and personalized treatment strategies, improving patient outcomes. The market reached a value of approximately USD 879.29 Million in 2025.
Strategic AI-Genomics Collaborations Driving the Market Value
Rising demand for precision therapeutics and faster target identification is driving strategic AI-genomics collaborations. For instance, in October 2025, AstraZeneca signed a USD 555 million partnership with Algen to leverage AI and CRISPR technologies for identifying immunology targets and developing gene therapies. This collaboration highlights how integrating AI with genomics accelerates drug discovery, improves biological insights, and enhances pipeline efficiency. Such partnerships are expected to significantly drive AI in genomics market growth by reducing development timelines and increasing success rates in precision medicine.
Key trends shaping the global AI in genomics market include increasing investments, strategic collaborations, and acquisitions for the expansion of AI genomics capabilities.
Investments in AI-Driven Genomics Infrastructure Advancing Market Development Potential
Growing investments in AI-enabled genomics infrastructure are shaping long-term market development. For instance, in May 2025, BioNTech announced plans to invest up to 1 billion Pounds in the United Kingdom to expand AI-driven genomics research and personalized cancer treatment capabilities, including new R&D centers. This initiative reflects an increasing focus on integrating AI with genomic data for precision oncology. Such large-scale investments are expected to advance AI in genomics market development by strengthening research ecosystems, accelerating innovation, and expanding applications in personalized medicine globally.
Market Breakup by Component
Market Breakup by Functionality
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Software Expected to Lead the Market Share by Component
The market demonstrates a strong preference for software-driven solutions, reflecting the growing need for advanced data analytics and scalable platforms. Based on component, the software segment held the largest market share of approximately 42% in the historical period, supported by its critical role in genomic sequencing analysis, variant interpretation, and predictive modeling. The increasing adoption of cloud-based bioinformatics tools and machine learning algorithms is further accelerating segment growth. Additionally, continuous innovation in AI-powered platforms is enhancing research efficiency, enabling faster insights, and strengthening the dominance of software within the market landscape.
The global AI in genomics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each contributing uniquely to market expansion. North America held the largest share of over 38% of the global market in the historical period, driven by strong biotechnology infrastructure, significant R&D investments, and early adoption of AI technologies. The presence of leading genomics companies and supportive regulatory frameworks further supports regional dominance. Meanwhile, Asia Pacific is expected to witness rapid growth due to expanding healthcare infrastructure and increasing genomics research initiatives.
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
International Business Machines Corporation (IBM), headquartered in Armonk, New York, and founded in 1911, is a global technology leader. In the AI in genomics market, IBM leverages its Watson platform to support genomic data analysis, clinical decision-making, and precision medicine initiatives. The company collaborates with healthcare institutions to integrate AI with genomic sequencing, enabling faster insights into disease mechanisms. Its portfolio includes cloud-based analytics, AI-driven healthcare solutions, and bioinformatics tools that enhance large-scale genomic research and personalized treatment development.
Headquartered in Redmond, Washington, and established in 1975, Microsoft Corporation is a leading technology company driving innovation in AI and cloud computing. In the AI in genomics market, Microsoft offers solutions through Azure, enabling scalable genomic data storage, processing, and analysis. Its AI tools support researchers in decoding complex genetic data and accelerating precision medicine. Microsoft collaborates with biotech firms and research organizations to advance genomics-based healthcare. Its portfolio includes AI-powered analytics, cloud infrastructure, and machine learning platforms tailored for life sciences.
Founded in 1993 and headquartered in Santa Clara, California, NVIDIA Corporation is a pioneer in accelerated computing and AI technologies. In the AI in genomics market, NVIDIA provides high-performance GPUs and AI frameworks that power genomic sequencing, variant analysis, and drug discovery. Its platforms, such as NVIDIA Clara, enable researchers to process massive genomic datasets efficiently. The company collaborates with healthcare and biotech organizations to accelerate precision medicine. Its portfolio includes AI computing infrastructure, deep learning tools, and specialized healthcare solutions.
Founded in 2015 and headquartered in Toronto, Canada, Deep Genomics is a biotechnology company focused on applying AI to genomic medicine. The company uses deep learning to identify genetic mutations and predict their impact on RNA biology, enabling the discovery of novel therapeutic targets. Its proprietary AI platform analyzes vast genomic datasets to accelerate drug development, particularly for rare and genetic diseases. Deep Genomics’ portfolio includes AI-driven drug discovery programs and partnerships aimed at advancing precision medicine and RNA-based therapeutics.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are Data4Cure, Inc., Freenome Holdings, Inc., SOPHiA GENETICS, Thermo Fisher Scientific Inc., Illumina, Inc., and BenevolentAI.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Component |
|
| Breakup by Functionality |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share